Anzeige
Mehr »
Mittwoch, 11.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
44 Leser
Artikel bewerten:
(0)

United States On-Pump Coronary Artery Bypass Devices Market 2017-2018

DUBLIN, Dec. 22, 2017 /PRNewswire/ --

The "US Market Report for On-Pump Coronary Artery Bypass Devices 2018 - MedCore" report has been added to Research and Markets' offering.

Research and Markets Logo

There are some downsides to the use of CPB pumps. Use of the CPB for circulation exposes the patient's blood to foreign surfaces, which has been shown to increase the incidence of bleeding and short-term neurocognitive defects. This is known as post-perfusion syndrome or pump head. Symptoms of post-perfusion syndrome are subtle and include defects associated with attention, concentration, short-term memory, fine motor function and speed of mental and motor responses.


Additionally, stopping of the heart may damage the heart muscle. In certain studies, clamping of the aorta has been shown in certain studies to cause the release of particles into the blood stream that may produce blockages in other parts of the body, such as the brain, which may lead to neurological damage, including strokes. Despite these potential complications, the majority of CABG procedures are still performed on-pump.

Furthermore, the percentage of total CABG procedures performed on-pump has been increasing year-over-year since 2004.

The majority of coronary artery bypass graft (CABG) procedures are performed with the heart stopped. This type of procedure is termed on-pump coronary artery bypass (ONCAB) because the procedure requires the usage of a cardiopulmonary bypass (CPB). CPB is a technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the body.

The CPB pump itself is often referred to as a heart-lung machine. In addition to the heart-lung machine, a complete extracorporeal bypass system is composed of various single-use products, called disposables for the purposes of this report. As disposables come into direct contact with the patient's blood, they cannot be reused for safety reasons and must be disposed of and replaced following each procedure.

Key Topics Covered:

Executive Summary
U.S. Cardiac Surgery And Heart Valve Device Market Overview
Competitive Analysis
Market Trends
Market Developments
Procedure Numbers
Procedure Codes Investigated
Markets Included
Key Report Updates
Version History

1. Research Methodology

2. Disease Overview
2.1 Basic Anatomy
2.1.1 Coronary Artery Disease
2.1.2 Myocardial Infarction
2.1.3 Angina Pectoris
2.1.4 Heart Valve Disease
2.1.5 Congestive Heart Failure

3. Product Portfolio
3.1.1 Tissue Heart Valves
3.1.2 Mechanical Tissue Heart Valves
3.1.3 Annuloplasty Repair Devices
3.1.4 Transcatheter Aortic Valve Replacement Devices
3.1.5 Transcatheter Mitral Valve Repair Devices
3.1.6 On-Pump Coronary Artery Bypass Devices
3.1.7 Off-Pump Coronary Artery Bypass Devices
3.1.8 Endoscopic Vessel Harvesting Devices
3.1.9 Anastomosis Assist Devices
3.1.10 Transmyocardial Revascularization Devices
3.1.11 Ventricular Assist Devices
3.1.12 Intra-Aortic Balloon Pump Device
3.1.13 Temporary Artificial Heart Replacement Device
3.1.14 Remote Hemodynamic Monitoring System Devices
3.1.15 Patent Foramen Ovale Devices
3.1.16 Atrial & Ventricular Septal Defect Device
3.1.17 Left Atrial Appendage Closure Device
3.1.18 Extracorporeal Membrane Oxygenation Machine
3.2 Fda Recalls
3.3 Clinical Trials

4. On-Pump Coronary Artery Bypass Device Market
4.1 Introduction
4.2 Market Overview
4.3 Market Analysis And Forecast
4.3.1 On-Pump Coronary Artery Bypass Disposables Market
4.3.2 Perfusion System Market
4.4 Drivers And Limiters
4.5 Competitive Market Share Analysis

Companies Mentioned

  • Edwards Lifesciences
  • St. Jude Medical
  • Medtronic
  • Maquet
  • Abiomed
  • HeartWare Inc.
  • Sorin Group
  • Terumo
  • Abbott Laboratories
  • Teleflex Medical
  • Cardiac Assist
  • AtriCure
  • W.L. Gore
  • SynCardia
  • Boston Scientific
  • Cryolife
  • Berlin Heart
  • Cardica
  • Chase Medical
  • Genesee Biomedical
  • Karl Storz
  • LifeNet Health
  • Microline Surgical
  • Novadaq
  • On-X
  • Saphena Medical
  • SentreHeart
  • Vitalitec

For more information about this report visit https://www.researchandmarkets.com/research/tvqbgw/united_states?w=5

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

© 2017 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.